---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-24-000057"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:22:33.587591+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance

## Summary
- Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).
- Adjusted net income $1.2M (first profitable quarter); GAAP net loss $8.3M.
- Adjusted gross margin 64%, up from 48% YoY.
- FY 2024 revenue guidance raised to $284–290M (prev. $255–265M).
- Cash use improved 88% YoY to $5.0M; $117.4M cash as of Sept. 30, 2024.

## SEC filing metadata
- accession: 0001818331-24-000057
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000057/0001818331-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000057/wgs-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-24-000057
- JSON: https://secwatch.observer/filing/0001818331-24-000057.json
- Plain text: https://secwatch.observer/filing/0001818331-24-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.